Resumo
Diretriz confiável
ebpracticenet recomenda que você priorize as seguintes diretrizes locais:
Recommendations nationales de bonne pratique pour la prise en charge du cancer localisé de la prostate: première partiePublicada por: KCEÚltima publicação: 2014Nationale praktijkrichtlijn voor de aanpak van gelokaliseerde prostaatkanker: deel 1Publicada por: KCEÚltima publicação: 2014Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- antígeno prostático específico (PSA) elevado
Outros fatores diagnósticos
- exame de toque retal (ETR) anormal
- noctúria
- polaciúria
- hesitação urinária
- disúria
- hematúria
- perda de peso/anorexia
- letargia
- dor óssea
- linfonodos palpáveis
Fatores de risco
- idade >50 anos
- etnia negra
- Populações do noroeste da Europa, Caribe, Austrália, Nova Zelândia, América do Norte e sul da África
- história familiar positiva/fatores genéticos
- alimentação com alto teor de gordura
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- antígeno prostático específico (PSA) sérico
- RNM multiparamétrica pré-biópsia
- biópsia de próstata
Investigações a serem consideradas
- testagem de biomarcadores pré-biópsia
- testosterona
- TFHs
- Hemograma completo
- função renal
- cintilografia óssea (tecnécio-99)
- Tomografia computadorizada (TC)
- RNM
- antígeno de membrana específico da próstata (PSMA)-PET/CT
- PSMA-PET/MRI
- testes genéticos e moleculares
Algoritmo de tratamento
Colaboradores
Autores
Timothy J. Wallace, MD, PhD
Radiation Oncologist
Department of Radiation Oncology
Virginia Commonwealth University
Richmond
VA
Declarações
TJW declares that he has no competing interests.
Mitchell S. Anscher, MD, FACR, FACRO, FASTRO
Professor Emeritus
Department of Radiation Oncology
Virginia Commonwealth University
Richmond
VA
Declarações
MSA declares that he has no competing interests.
Revisores
Emma Alexander, MBBS
Clinical Oncology Registrar
St Luke's Cancer Centre
Royal Surrey Hospital
Guildford
Surrey
UK
Declarações
EA has received consultation fees from the following organisations: Blue Cross/Blue Shield Association, Sanofi-Aventis, Ferring Pharmaceuticals, Pfizer Corporation, American Urological Association, National Institutes of Health, Accreditation Council for Graduate Medical Education, Royal Hallamshire Hospital, Hartford County Medical Association. EA owns shares in Pfizer Pharmaceuticals, Johnson and Johnson, and General Electric Corporation.
Peter Albertsen, MD
Medical Director
UConn Medical Group
University of Connecticut Health Center
Farmington
CT
Declarações
PA declares that he has no competing interests.
Patrick C. Walsh, MD
University Distinguished Service Professor of Urology
Professor Emeritus of Urology
Brady Urological Institute
Johns Hopkins University
Baltimore
MD
Declarações
PCW declares that he has no competing interests.
James Kearns, MD
Assistant Professor of Urology
NorthShore University HealthSystem
Chicago
IL
Declarações
JK declares that he has no competing interests. JK is an author of an article cited in the topic.
Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer [internet publication].Texto completo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection [internet publication].Texto completo
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119-34.Texto completo Resumo
Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018 Oct 11;36(34):JCO1801097.Texto completo Resumo
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-mMaking at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024 Apr;211(4):509-17.Texto completo Resumo
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. J Urol. 2024 Apr;211(4):518-25.Texto completo Resumo
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol. 2024 Apr;211(4):526-32.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível aqui.
O uso deste conteúdo está sujeito ao nosso aviso legal